Clinical ReadoutsRoche will deliver a substantial number of clinical readouts, which can decide a turnaround to the story.
Growth MomentumRoche's strong high-single-digit growth momentum is expected to persist, supported by an updated chart suggesting undervaluation of its pipeline.
Sales And PerformanceThree potential assets are forecasted to generate over $5bn in sales, with Giredestrant for breast cancer showing the highest conviction.